FINANCIAL TIMES | The FT’s Andrew Jack explores the question of how to incentivize the development of new antibiotics. An informative 4:49-minute video. More countries must provide the right incentives to develop drugs to combat antibiotic resistance. Jack explores the idea of tackling the growing global health threat by de-linking incentive payments to pharmaceutical companies from sales, offering pharma companies guaranteed income for innovative treatments rather than rewarding them with volume of sales.